XL184、LUCICABOZ、Caboxen、Cazanat、卡博替尼片

Cabozantinib

Another Name
XL184、LUCICABOZ、Caboxen、Cazanat
Indications
Cabozantinib has been approved for the treatment of various cancers.
Reg No
05 L 0971/23
Inspection No
0747-23
dosage form:Tablets
Specs:20 mg*90tablets
Indate:24 months
Date：2024-9-1 Views：1034
Drug Info

COMPOSITION:

EACH FILM-COATED LUCICABOZ TABLET CONTAINS: Cabozantinib 20mg

INDICATION:

LuciCaboz a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).

DOSAGE AND USE:

Recommended Dose: 140 mg orally, once daily. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking LuciCaboz.

STORAGE:

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Keep medicine out of the reach of Children.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING AND PRECAUTION:

To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/cabozantinib/

Related News